• Bloomberg Quicktake: Now
• 20 Nov, 2019

Pharma companies have invested in phage therapy as a possible answer to antibiotic resistance. Joel Grimwood was dying. A bacterial slime impervious to antibiotics was growing on a life-sustaining heart implant, infecting his sternum, poisoning his blood, and slowly consuming his chest tissue. His implanted heart pump was meant to be a short-term solution while he waited for a heart transplant but, once it was infected, it couldn’t be safely removed.
Read more...